Funding for this research was provided by:
Innovative Medicines Initiative (116020)
Received: 16 March 2020
Accepted: 6 November 2020
First Online: 18 November 2020
Ethics approval and consent to participate
: Ethical approval was not required because all work was carried out using previously published studies.
: Not applicable
: YC is an employee of F. Hoffmann-La Roche Ltd. RH has received grants from ROADMAP (IMI2; public–private collaboration; 2016–2019); consulting fees from Piramal, Roche and Eisai; and grants from Horizon 2020, JPND Joint Programming Neurodegenerative Disease Research, IMI Innovative Medicines Initiative, and national, European and patient charity funding organisations and private–public collaborations (ZonMw Netherlands, Alzheimer Netherlands, Dutch Flutemetamol Study, Alzheimer Research UK, Swedish National study on Aging and Care, European Brain Council). PL is employed by, owns stock in and has stock options in Novartis Pharma AG. AG is a partner of Quantify Research, providing consultancy services to pharmaceutical companies and other private and public organisations and institutions. AG’s contribution to ROADMAP was on behalf of Roche Pharmaceuticals. ERD is an employee of GE Healthcare. MB is an employee of and owns stock in Eli Lilly and Company Limited. GSJ is an employee of F. Hoffmann-La Roche Ltd. MHP is an employee of Biogen and owns stock in Biogen. She owns stock in a variety of companies that at times include other pharmaceutical and healthcare-related companies. ATH is an employee of and owns stock in Eli Lilly and Company Limited. FL, SM, KW, EN, JM, HW, IG, JL, NR, HW, JCB and AMG declare that they have no competing interests.